退伍军人事务部医疗系统中睾丸癌幸存者良性前列腺增生的发病率

Kshitij Pandit, Paul Riviere, Kylie Morgan, Aditya Bagrodia
{"title":"退伍军人事务部医疗系统中睾丸癌幸存者良性前列腺增生的发病率","authors":"Kshitij Pandit, Paul Riviere, Kylie Morgan, Aditya Bagrodia","doi":"10.1101/2024.09.14.24313693","DOIUrl":null,"url":null,"abstract":"Abstract:\nTestosterone and prostatic inflammation have been postulated to influence the development of benign prostatic hyperplasia (BPH). Our study aims to evaluate the incidence of BPH in Testicular Cancer (TCa) survivors, focusing on the impact of chemotherapy and post TCa diagnosed hypogonadism. We conducted a retrospective cohort analysis of US veterans diagnosed with TCa between 1990 to 2021, using the Veterans affairs database. BPH was defined using International Classification of Diseases (ICD) codes, Current Procedural Terminology (CPT) codes, or a 6-month prescription of medications. Associations with BPH were analysed, stratifying the cohort by receipt of chemotherapy and presence of hypogonadism. Multivariable cox regression models were used to determine statistical significance (p-value <0.05). Our cohort included 2038 TCa survivors with a median age at diagnosis of 41 years. On multivariable cox regression analysis, receipt of chemotherapy was not significantly associated with incidence of BPH (p-value= 0.13). When stratified by diagnosis of hypogonadism prior to BPH, no significant associations were found on univariable (p=0.81) as well as multivariable (p=0.65) analyses. In the multivariable model, age at diagnosis was significantly associated with an increased incidence of BPH (Hazard ratio: 1.06, p<0.001). Our findings demonstrate that age is a significant factor associated with development of BPH in this population, while suggesting that chemotherapy for TCa and hypogonadism might not substantially alter the development of BPH.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"INCIDENCE OF BENIGN PROSTATIC HYPERPLASIA IN TESTICULAR CANCER SURVIVORS IN THE VETERANS AFFAIRS HEALTH SYSTEM\",\"authors\":\"Kshitij Pandit, Paul Riviere, Kylie Morgan, Aditya Bagrodia\",\"doi\":\"10.1101/2024.09.14.24313693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract:\\nTestosterone and prostatic inflammation have been postulated to influence the development of benign prostatic hyperplasia (BPH). Our study aims to evaluate the incidence of BPH in Testicular Cancer (TCa) survivors, focusing on the impact of chemotherapy and post TCa diagnosed hypogonadism. We conducted a retrospective cohort analysis of US veterans diagnosed with TCa between 1990 to 2021, using the Veterans affairs database. BPH was defined using International Classification of Diseases (ICD) codes, Current Procedural Terminology (CPT) codes, or a 6-month prescription of medications. Associations with BPH were analysed, stratifying the cohort by receipt of chemotherapy and presence of hypogonadism. Multivariable cox regression models were used to determine statistical significance (p-value <0.05). Our cohort included 2038 TCa survivors with a median age at diagnosis of 41 years. On multivariable cox regression analysis, receipt of chemotherapy was not significantly associated with incidence of BPH (p-value= 0.13). When stratified by diagnosis of hypogonadism prior to BPH, no significant associations were found on univariable (p=0.81) as well as multivariable (p=0.65) analyses. In the multivariable model, age at diagnosis was significantly associated with an increased incidence of BPH (Hazard ratio: 1.06, p<0.001). Our findings demonstrate that age is a significant factor associated with development of BPH in this population, while suggesting that chemotherapy for TCa and hypogonadism might not substantially alter the development of BPH.\",\"PeriodicalId\":501140,\"journal\":{\"name\":\"medRxiv - Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.14.24313693\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.14.24313693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

摘要:睾酮和前列腺炎症被认为会影响良性前列腺增生症(BPH)的发生。我们的研究旨在评估睾丸癌(TCa)幸存者良性前列腺增生症的发病率,重点关注化疗和TCa确诊后性腺功能减退的影响。我们利用退伍军人事务数据库对 1990 年至 2021 年期间确诊为睾丸癌的美国退伍军人进行了回顾性队列分析。良性前列腺增生症是根据国际疾病分类 (ICD) 代码、当前程序术语 (CPT) 代码或 6 个月的药物处方定义的。根据接受过化疗和是否存在性腺功能减退症对队列进行了分层,分析了前列腺增生症的相关性。多变量 COX 回归模型用于确定统计学意义(P 值为 0.05)。我们的队列包括 2038 名 TCa 幸存者,确诊时的中位年龄为 41 岁。经多变量 cox 回归分析,接受化疗与良性前列腺增生症的发病率无显著相关性(p 值= 0.13)。如果根据前列腺增生症之前的性腺功能减退症诊断进行分层,在单变量(p=0.81)和多变量(p=0.65)分析中均未发现明显的相关性。在多变量模型中,诊断时的年龄与良性前列腺增生症发病率的增加有明显相关性(危险比:1.06,p<0.001)。我们的研究结果表明,在这一人群中,年龄是与良性前列腺增生症发病相关的一个重要因素,同时也表明 TCa 化疗和性腺功能减退症可能不会在很大程度上改变良性前列腺增生症的发病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
INCIDENCE OF BENIGN PROSTATIC HYPERPLASIA IN TESTICULAR CANCER SURVIVORS IN THE VETERANS AFFAIRS HEALTH SYSTEM
Abstract: Testosterone and prostatic inflammation have been postulated to influence the development of benign prostatic hyperplasia (BPH). Our study aims to evaluate the incidence of BPH in Testicular Cancer (TCa) survivors, focusing on the impact of chemotherapy and post TCa diagnosed hypogonadism. We conducted a retrospective cohort analysis of US veterans diagnosed with TCa between 1990 to 2021, using the Veterans affairs database. BPH was defined using International Classification of Diseases (ICD) codes, Current Procedural Terminology (CPT) codes, or a 6-month prescription of medications. Associations with BPH were analysed, stratifying the cohort by receipt of chemotherapy and presence of hypogonadism. Multivariable cox regression models were used to determine statistical significance (p-value <0.05). Our cohort included 2038 TCa survivors with a median age at diagnosis of 41 years. On multivariable cox regression analysis, receipt of chemotherapy was not significantly associated with incidence of BPH (p-value= 0.13). When stratified by diagnosis of hypogonadism prior to BPH, no significant associations were found on univariable (p=0.81) as well as multivariable (p=0.65) analyses. In the multivariable model, age at diagnosis was significantly associated with an increased incidence of BPH (Hazard ratio: 1.06, p<0.001). Our findings demonstrate that age is a significant factor associated with development of BPH in this population, while suggesting that chemotherapy for TCa and hypogonadism might not substantially alter the development of BPH.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信